Skip to content
Wolverine Safe

A studio-rendered safety brief on the Wolverine peptide blend — BPC-157 and TB-500 turned on the turntable, the tumor/angiogenesis signal and the regulatory-access record kept in view.

07 // STUDIES AND FDA PAGES

Where are the BPC-157 TB-500 studies and FDA pages?

The cited tests measured healing, cell movement, and safety of separate ingredients. No human trial tested the BPC-157 TB-500 pair among these sources. The number next to a claim matches the numbered entry below. You can open that paper or FDA page to check the claim.

Return to safety findingsRead the pharmacy discussion

How can you find the paper behind a claim?

Sources 1 through 10 support the BPC-157 TB-500 healing and safety discussion. Source 5 concerns Thymosin Beta-4 and tumors; source 6 describes mice growing new muscle fibers without stronger muscles. Source 11 covers research amounts, timing, sports rules, and human findings. For pharmacy permission, sources 12 through 15 lead you to FDA's pages.

The details below let a doctor or lab identify the exact ingredients; you don't need to read the letter strings to follow the findings. BPC-157 has the list of parts GEPPPGKPADDAGLV, chemical makeup C62H98N16O22, and weight MW ~1419.5 Da; MW means weight, and Da means daltons, the lab unit. Its record numbers are CAS 137525-51-0 and PubChem CID 108101, which identify the substance rather than an injury study. TB-500 has list of parts Ac-LKKTETQ, makeup C38H68N10O14, and weight ~889.0 Da; complete Thymosin Beta-4 has record number UniProt P62328, and none of these identifiers proves your safety.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95(22):1674-1680. ↗
  6. Spurney CF, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010;5(1):e8976. ↗
  7. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  8. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  10. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  11. Compiled dosage, pharmacokinetic, route, WADA, and human-data context for BPC-157 and TB-500 / thymosin beta-4 from the audited Wolverine compound corpus (research summaries of rodent dose-response, rat/dog PK, and Phase 1 full-length thymosin beta-4 studies). Research context only; not human dosing guidance. ↗
  12. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; effective with the September 29, 2023 update to the nominated-substances list.) ↗
  13. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2, the 503A/503B framework, and the bulks-list nomination process.) ↗
  14. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page; finalized January 2025). ↗
  15. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500 among bulk drug substances 'being considered for inclusion on the 503A Bulks List'; a scheduled discussion, not a decision.) ↗
  16. Ho ENM, et al.. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  17. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  18. et al.. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗